Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) insider Nerissa Kreher sold 800 shares of the business’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $15.07, for a total transaction of $12,056.00. Following the sale, the insider now directly owns 20,716 shares of the company’s stock, valued at $312,190.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Entrada Therapeutics Stock Down 20.2 %
NASDAQ:TRDA traded down $3.01 during mid-day trading on Monday, reaching $11.91. The company’s stock had a trading volume of 145,890 shares, compared to its average volume of 90,913. Entrada Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $36.85. The stock has a fifty day moving average of $12.22 and a 200-day moving average of $9.74. The firm has a market capitalization of $373.59 million and a PE ratio of -0.98.
Wall Street Analysts Forecast Growth
Separately, The Goldman Sachs Group upped their price objective on shares of Entrada Therapeutics from $10.00 to $13.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 16th.
Institutional Trading of Entrada Therapeutics
Ad Legacy Research
We are about to witness a huge economic crisis…
We all know the mainstream media will say anything for more viewers and clicks…
But folks who are distracted by this kind of propaganda are about to be left behind.
A number of hedge funds have recently added to or reduced their stakes in the business. Laurion Capital Management LP purchased a new stake in Entrada Therapeutics in the second quarter worth about $1,572,000. Millennium Management LLC bought a new position in Entrada Therapeutics in the second quarter worth about $932,000. FMR LLC raised its holdings in Entrada Therapeutics by 7.8% in the second quarter. FMR LLC now owns 944,908 shares of the company’s stock worth $11,509,000 after purchasing an additional 68,114 shares in the last quarter. Walleye Capital LLC bought a new position in Entrada Therapeutics in the first quarter worth about $419,000. Finally, State Street Corp raised its holdings in Entrada Therapeutics by 86.4% in the first quarter. State Street Corp now owns 151,194 shares of the company’s stock worth $1,420,000 after purchasing an additional 70,075 shares in the last quarter. 79.02% of the stock is owned by hedge funds and other institutional investors.
About Entrada Therapeutics
Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company’s lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entrada Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Entrada Therapeutics wasn’t on the list.
While Entrada Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Sells 800 Shares of